Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir
出版年份 2018 全文链接
标题
Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir
作者
关键词
HIV-1, Integrase inhibitors, Antiretroviral drug resistance, Cell culture selections, Primary HIV infection isolates, HIV subtypes
出版物
Retrovirology
Volume 15, Issue 1, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-08-17
DOI
10.1186/s12977-018-0440-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors
- (2018) Tomokazu Yoshinaga et al. ANTIVIRAL RESEARCH
- Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen
- (2018) Charlotte Charpentier et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Resistance to Dolutegravir—A Chink in the Armor?
- (2018) Daniel R Kuritzkes JOURNAL OF INFECTIOUS DISEASES
- HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy
- (2018) Ingeborg E A Wijting et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
- (2018) Steven J. Smith et al. Retrovirology
- Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations
- (2018) et al. Viruses-Basel
- HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters
- (2017) Bluma G. Brenner et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
- (2017) David A Margolis et al. LANCET
- Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2017) Paul E Sax et al. LANCET
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
- (2017) Joel Gallant et al. LANCET
- HIV drug resistance against strand transfer integrase inhibitors
- (2017) Kaitlin Anstett et al. Retrovirology
- Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance
- (2017) Bluma G. Brenner et al. VIRUS RESEARCH
- Genotypic and Phylogenetic Insights on Prevention of the Spread of HIV-1 and Drug Resistance in “Real-World” Settings
- (2017) Bluma Brenner et al. Viruses-Basel
- Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
- (2017) Paul E Sax et al. Lancet HIV
- Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors
- (2016) Bluma G. Brenner et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges
- (2016) Johannes Carl Christoph Lenz et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B
- (2015) Thibault Mesplède et al. AIDS
- HIV Drug Resistance Testing by High-Multiplex “Wide” Sequencing on the MiSeq Instrument
- (2015) H. R. Lapointe et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout
- (2015) Nathan Osman et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial
- (2015) David A Margolis et al. LANCET INFECTIOUS DISEASES
- Long-acting antiviral agents for HIV treatment
- (2015) David A. Margolis et al. Current Opinion in HIV and AIDS
- Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase
- (2015) Peter K. Quashie et al. JOURNAL OF VIROLOGY
- Integrase strand transfer inhibitors in the management of HIV-positive individuals
- (2014) Thibault Mesplède et al. ANNALS OF MEDICINE
- Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection
- (2014) Tomokazu Yoshinaga et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Performance of HIV-1 Drug Resistance Testing at Low-Level Viremia and Its Ability to Predict Future Virologic Outcomes and Viral Evolution in Treatment-Naive Individuals
- (2014) A. Gonzalez-Serna et al. CLINICAL INFECTIOUS DISEASES
- Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity
- (2014) T. Mesplede et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness
- (2014) Melissa Wares et al. Retrovirology
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
- (2013) Thibault Mesplède et al. Retrovirology
- Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline
- (2012) Eugene L. Asahchop et al. AIDS
- Uncommon Pathways of Immune Escape Attenuate HIV-1 Integrase Replication Capacity
- (2012) M. A. Brockman et al. JOURNAL OF VIROLOGY
- Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes
- (2011) Kendra E. Hightower et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors
- (2011) Bluma G. Brenner et al. JOURNAL OF MEDICAL VIROLOGY
- Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir
- (2011) P. K. Quashie et al. JOURNAL OF VIROLOGY
- Development of Antiretroviral Drug Resistance
- (2011) Mark A. Wainberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays
- (2010) Tamara Bar-Magen et al. AIDS
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Novel integrase inhibitors for HIV
- (2010) Nicole Prada et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism
- (2010) N. Gonzalez et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In Vivo
- (2009) O. Delelis et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Panel of Prototypical Raltegravir-Resistant Infectious Molecular Clones in a Novel Integrase-Deleted Cloning Vector
- (2009) E. C. Reuman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients
- (2009) I. Malet et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen
- (2009) J. Ghosn et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro
- (2008) I. Malet et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started